Palo Alto – March 1, 2017 – Cooley advised Freenome on its $65 million Series A financing round. Andreessen Horowitz led the round, which also included existing investors Data Collective and Founders Fund, as well as new investors GV (Google Ventures), Polaris Partners, Innovation Endeavors, Asset Management Ventures, Charles River Ventures and Spectrum 28.
“This funding will allow us to increase the number of clinical trials in collaboration with top researchers and clinicians around the world, enabling us to bring our product to market more quickly and equip people with knowledge and tools to live healthier lives,” said Freenome cofounder Gabe Otte in a press release issued by the company.
Freenome is a health technology company bringing accurate, accessible and non-invasive disease screenings to proactively treat cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.